医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2015年
22期
146-147
,共2页
醛固酮受体拮抗剂%螺内酯%难治性高血压%临床疗效
醛固酮受體拮抗劑%螺內酯%難治性高血壓%臨床療效
철고동수체길항제%라내지%난치성고혈압%림상료효
Aldosterone receptor antagonist%Spironolactone%Refractory hypertension%Clinical efficacy
目的：观察难治性高血压患者采用螺内酯治疗的临床效果。方法：选择难治性高血压患者82例作为研究对象，该组患者经包含利尿剂在内的三种及以上降压药治疗8周以上血压仍不能控制者（对照组）；对照组患者转为研究组，治疗方案为血管紧张素转换酶抑制剂/血管紧张素受体拮抗剂＋钙离子拮抗剂＋利尿剂+螺内酯，对两组患者的血压变化、电解质、肾功能、动脉弹性、心脏超声功能及药物的安全性进行对比及观察分析。结果：研究组患者在血压改善上要明显优于对照组；动脉脉搏波传导速（P W V）值明显减小；LVEDD、LVESD、LVEF、FS均有明显好转，有显著性差异（P＜0.05）；未见明显不良反应。结论：对于难治性高血压患者，加用螺内酯可以明显控制患者血压，改善心脏和血管的功能，值得临床借鉴。
目的：觀察難治性高血壓患者採用螺內酯治療的臨床效果。方法：選擇難治性高血壓患者82例作為研究對象，該組患者經包含利尿劑在內的三種及以上降壓藥治療8週以上血壓仍不能控製者（對照組）；對照組患者轉為研究組，治療方案為血管緊張素轉換酶抑製劑/血管緊張素受體拮抗劑＋鈣離子拮抗劑＋利尿劑+螺內酯，對兩組患者的血壓變化、電解質、腎功能、動脈彈性、心髒超聲功能及藥物的安全性進行對比及觀察分析。結果：研究組患者在血壓改善上要明顯優于對照組；動脈脈搏波傳導速（P W V）值明顯減小；LVEDD、LVESD、LVEF、FS均有明顯好轉，有顯著性差異（P＜0.05）；未見明顯不良反應。結論：對于難治性高血壓患者，加用螺內酯可以明顯控製患者血壓，改善心髒和血管的功能，值得臨床藉鑒。
목적：관찰난치성고혈압환자채용라내지치료적림상효과。방법：선택난치성고혈압환자82례작위연구대상，해조환자경포함이뇨제재내적삼충급이상강압약치료8주이상혈압잉불능공제자（대조조）；대조조환자전위연구조，치료방안위혈관긴장소전환매억제제/혈관긴장소수체길항제＋개리자길항제＋이뇨제+라내지，대량조환자적혈압변화、전해질、신공능、동맥탄성、심장초성공능급약물적안전성진행대비급관찰분석。결과：연구조환자재혈압개선상요명현우우대조조；동맥맥박파전도속（P W V）치명현감소；LVEDD、LVESD、LVEF、FS균유명현호전，유현저성차이（P＜0.05）；미견명현불량반응。결론：대우난치성고혈압환자，가용라내지가이명현공제환자혈압，개선심장화혈관적공능，치득림상차감。
Objective To observe patients with refractory hypertension clinical effects of spironolactone therapy. Methods 82 patients with refractory hypertension as research subjects, this group included patients with diuretics, including three or more antihypertensive drug therapy is still not more than eight weeks of blood pressure control (control group);control group of patients transferred for the study group, the treatment options for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers+diuretics, calcium antagonists++spironolactone, two groups of patients for changes in blood pressure, electrolytes, renal function, arterial elasticity, heart comparison and analysis of observed and drug safety functions performed ultrasound. Results The study group on the blood pressure of patients improve significantly better than the control group;arterial pulse wave velocity (PWV) value is significantly reduced;LVEDD, LVESD, LVEF, FS were significantly improved, there was a significant difference (P<0.05);no significant adverse reactions. Conclusion For patients with refractory hypertension, the addition of spironolactone can significantly control the blood pressure, improve the function of the heart and blood vessels, is worthy of reference.
